title: Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders.
abstract: Fibroblast growth factor (FGF) 21 is a member of the endocrine FGF subfamily. FGF21 expression is induced under different disease conditions, such as type 2 diabetes, obesity, chronic kidney diseases, and cardiovascular diseases, and it has a broad spectrum of functions in regulating various metabolic parameters. Many different approaches have been pursued targeting FGF21 and its receptors to develop therapeutics for treating type 2 diabetes and other aspects of metabolic conditions. In this article, we summarize some of these key approaches and highlight the potential challenges in the development of these agents.
authors.affiliation: Amgen Inc. , South San Francisco, CA , USA.
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Amgen Inc. , South San Francisco, CA , USA.
authors.forename: Yang
authors.initials: Y
authors.lastname: Li
keywords: FGF19; FGF21; FGFR1; antibody; beta-Klotho; diabetes; obesity; therapy